These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27070264)

  • 21. Reprogramming bladder cancer cells for studying cancer initiation and progression.
    Iskender B; Izgi K; Canatan H
    Tumour Biol; 2016 Oct; 37(10):13237-13245. PubMed ID: 27456363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.
    Bilousova G; Roop DR
    Cold Spring Harb Perspect Med; 2014 Nov; 4(11):a015164. PubMed ID: 25368014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.
    Menendez JA; Alarcón T; Corominas-Faja B; Cuyàs E; López-Bonet E; Martin AG; Vellon L
    Cell Cycle; 2014; 13(3):358-70. PubMed ID: 24406535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging methods for preparing iPS cells.
    Miyazaki S; Yamamoto H; Miyoshi N; Takahashi H; Suzuki Y; Haraguchi N; Ishii H; Doki Y; Mori M
    Jpn J Clin Oncol; 2012 Sep; 42(9):773-9. PubMed ID: 22826352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reprogramming of human cancer cells to pluripotency for models of cancer progression.
    Kim J; Zaret KS
    EMBO J; 2015 Mar; 34(6):739-47. PubMed ID: 25712212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated analysis of hematopoietic differentiation outcomes and molecular characterization reveals unbiased differentiation capacity and minor transcriptional memory in HPC/HSC-iPSCs.
    Gao S; Hou X; Jiang Y; Xu Z; Cai T; Chen J; Chang G
    Stem Cell Res Ther; 2017 Jan; 8(1):13. PubMed ID: 28114969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced human somatic cell reprogramming efficiency by fusion of the MYC transactivation domain and OCT4.
    Wang L; Huang D; Huang C; Yin Y; Vali K; Zhang M; Tang Y
    Stem Cell Res; 2017 Dec; 25():88-97. PubMed ID: 29125994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in reprogramming-based study of neurologic disorders.
    Nityanandam A; Baldwin KK
    Stem Cells Dev; 2015 Jun; 24(11):1265-83. PubMed ID: 25749371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purification of functional reprogramming factors in mammalian cell using FLAG -Tag.
    Han MJ; Kim HR; O'Reilly C; Kim CH
    Biochem Biophys Res Commun; 2017 Oct; 492(2):154-160. PubMed ID: 28802578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concise review: dedifferentiation meets cancer development: proof of concept for epigenetic cancer.
    Yamada Y; Haga H; Yamada Y
    Stem Cells Transl Med; 2014 Oct; 3(10):1182-7. PubMed ID: 25122691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Robust Differentiation of mRNA-Reprogrammed Human Induced Pluripotent Stem Cells Toward a Retinal Lineage.
    Sridhar A; Ohlemacher SK; Langer KB; Meyer JS
    Stem Cells Transl Med; 2016 Apr; 5(4):417-26. PubMed ID: 26933039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic predisposition to reprogramming fates in somatic cells.
    Pour M; Pilzer I; Rosner R; Smith ZD; Meissner A; Nachman I
    EMBO Rep; 2015 Mar; 16(3):370-8. PubMed ID: 25600117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induced pluripotent stem cells in medicine and biology.
    Takahashi K; Yamanaka S
    Development; 2013 Jun; 140(12):2457-61. PubMed ID: 23715538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
    Qi SD; Smith PD; Choong PF
    ANZ J Surg; 2014 Jun; 84(6):E1-11. PubMed ID: 23035845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcription factor-mediated reprogramming: epigenetics and therapeutic potential.
    Firas J; Liu X; Lim SM; Polo JM
    Immunol Cell Biol; 2015 Mar; 93(3):284-9. PubMed ID: 25643615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The triumph of chemically enhanced cellular reprogramming: a patent review.
    Anwar MA; Kim S; Choi S
    Expert Opin Ther Pat; 2016; 26(2):265-80. PubMed ID: 26593376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of Cancer Cell Reprogramming Technology to Human Cancer Research.
    Pan XY; Tsai MH; Wuputra K; Ku CC; Lin WH; Lin YC; Kishikawa S; Noguchi M; Saito S; Lin CS; Yokoyama KK
    Anticancer Res; 2017 Jul; 37(7):3367-3377. PubMed ID: 28668824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
    Qi SD; Smith PD; Choong PF
    ANZ J Surg; 2014 Jun; 84(6):417-23. PubMed ID: 24894037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells.
    Hu C; Li L
    Regen Med; 2016 Jan; 11(1):105-32. PubMed ID: 26679838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.